SightStream Biotherapeutics develops cytoprotective agents aimed at reversing ocular cell death caused by various retinal diseases. Their technology targets cellular stress responses to preserve vision and improve outcomes for patients suffering from degenerative eye conditions.
Funding
Funding not disclosed
Founders
Product
Problem
Retinal diseases often lead to irreversible ocular cell death, resulting in vision loss and limited treatment options for patients with degenerative eye conditions. Current therapies primarily address symptoms rather than directly protecting and preserving retinal cells from damage.
Solution
SightStream Biotherapeutics is developing cytoprotective agents designed to reverse ocular cell death associated with various retinal diseases. Their approach focuses on modulating cellular stress responses within the eye to promote cell survival and maintain visual function. By targeting the underlying mechanisms of retinal degeneration, SightStream aims to provide a disease-modifying therapy that preserves vision and improves long-term outcomes for patients. This technology offers a potential solution for individuals suffering from conditions such as age-related macular degeneration, diabetic retinopathy, and glaucoma.
Target Audience
The primary target audience includes patients suffering from retinal diseases such as age-related macular degeneration, diabetic retinopathy, and glaucoma, as well as ophthalmologists and retinal specialists seeking novel therapeutic options.
Features
- Cytoprotective agents targeting cellular stress responses in the retina
- Focus on reversing ocular cell death to preserve vision
- Potential application for various degenerative eye conditions